Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the Amer ...
December 1, 2023
– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductio ...Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Soc ...
November 21, 2023
– New data include 24-month results from the largest and longest prospective natural history study of children and adolescent ...Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 7, 2023
– STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 17, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 17, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 21, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Appoints Ian Smith to its Board of Directors
September 20, 2023
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genet ...Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet ...
September 5, 2023
– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in ...Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 7, 2023
– STK-001: Additional data from patients treated with single and multiple doses (70mg) along with data from open-label extens ...Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 2, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Aug. 2, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/ ...
July 25, 2023
– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reducti ...